Debio‐0719, a lysophosphatidic acid receptor 1 inhibitor, promotes breast cancer dormancy by decreasing proliferation markers Ki67 and ERK, while enhancing the p38 pathway, which suppresses growth [273]. Here, MKI67 is linked to breast carcinoma.